ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

TARS Tarsus Pharmaceuticals Inc

32.04
-0.17 (-0.53%)
Apr 26 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 381,058
Bid Price 29.39
Ask Price 100.00
News -
Day High 33.21

Low
12.57

52 Week Range

High
40.40

Day Low 31.26
Share Name Share Symbol Market Stock Type
Tarsus Pharmaceuticals Inc TARS NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.17 -0.53% 32.04 19:00:00
Open Price Low Price High Price Close Price Previous Close
32.57 31.26 33.21 32.04 32.21
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
7,123 381,058 US$ 31.93 US$ 12,168,028 - 12.57 - 40.40
Last Trade Type Quantity Price Currency
16:32:52 priorref 3,300 US$ 32.04 USD

Tarsus Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.1B 34.22M - 17.45M -135.89M -3.97 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Tarsus Pharmaceuticals News

Date Time Source News Article
4/23/202407:30GlobeNewswire Inc.Tarsus Strengthens Financial Position and Refinances..
3/11/202416:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
3/11/202416:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
3/11/202416:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
3/11/202416:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
3/05/202415:30GlobeNewswire Inc.Tarsus to Participate at Upcoming Investor Conferences
3/05/202415:09Edgar (US Regulatory)Form 8-K - Current report
3/05/202407:30GlobeNewswire Inc.Tarsus Introduces “Mite Party” Campaign for XDEMVY®..
3/01/202416:26Edgar (US Regulatory)Form 8-K - Current report
3/01/202416:17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
2/29/202423:07GlobeNewswire Inc.Tarsus Announces Pricing of $100.0 Million Public Offering
2/29/202416:08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TARS Message Board. Create One! See More Posts on TARS Message Board See More Message Board Posts

Historical TARS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week32.4434.3531.2632.58373,187-0.40-1.23%
1 Month36.5438.4631.2635.10525,854-4.50-12.32%
3 Months28.7240.4027.44533.81715,8453.3211.56%
6 Months13.0840.4012.8726.52696,87618.96144.95%
1 Year14.3240.4012.5723.27534,58117.72123.74%
3 Years30.5240.4010.800121.76236,4491.524.98%
5 Years18.3063.6910.800122.44212,12613.7475.08%

Tarsus Pharmaceuticals Description

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.

Your Recent History

Delayed Upgrade Clock